About the Webinar
3D epigenome remodeling is an important mechanism of gene deregulation in cancer. However, its potential as a target to overcome therapy resistance remains largely unaddressed. In this webinar, learn how researchers at the Garvan Institute used 3D genomics to explore mechanisms by which an FDA-approved epigenetic therapy can suppress tumor growth in ER+ breast cancer.

Key Takeaways
- Learn about 3D epigenome remodeling as an essential mechanism of gene deregulation in breast cancer.
- Understand the mechanisms by which Decitabine-induced DNA hypomethylation can suppress tumor growth in preclinical metastatic ER+ breast tumor xenograft models.
- Explore the potential of using epigenetic therapy to target ER+ endocrine-resistant breast cancer via DNA methylation-dependent rewiring of 3D chromatin interactions.

свернуть